Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models

Pharmacogenetics and Genomics

Volumn 23, Issue 3, 2013, Pages 167-174

  Bertrand, Julie ^a   Balding, David J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

nonlinear mixed effects models; penalized regression; pharmacogenetics; pharmacokinetics

Indexed keywords

ALTERNATIVE HYPOTHESIS; ARTICLE; CLASSICAL STEPWISE REGRESSION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HYPERLASSO REGRESSION ANALYSIS; LASSO REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NONLINEAR REGRESSION ANALYSIS; NULL HYPOTHESIS; PENALIZED REGRESSION ANALYSIS; PHARMACOGENETICS; PHARMACOKINETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RIDGE REGRESSION ANALYSIS; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84873412781     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835dd22c     Document Type: Article

References (24)

1. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, et al. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. Pharmacogenomics J 2009; 9:137-146.
2. EMEA. EMEA: reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products. London: EMEA; 2007.
3. Wu R, Tong C, Wang Z, Mauger D, Tantisira K, Szefler SJ, et al. A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics. Drug Discov Today 2011; 16:884-890.
4. Lehr T, Schaefer H-G, Staab A. Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. Pharmacogenet Genomics 2010; 20:442-450.
5. Ayers KL, Cordell HJ. SNP selection in genome-wide and candidate gene studies via penalized logistic regression. Genet Epidemiol 2010; 34: 879-891.
6. Tibshirani R. Regression shrinkage and selection via the Lasso. J Roy Statist Soc Ser B 1996; 58:267-288.
7. Hoggart CJ, Whittaker JC, De Iorio M, Balding DJ. Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies. PLoS Genet 2008; 4:e1000130.
8. Bertrand J, Mentré F, Lavielle M, Mesa H, Chatel K. Mathematical Expressions of the Pharmacokinetic and Pharmacodynamic Models implemented in the Monolix software. 2008. Available at: http://www.facm.ucl.ac.be/cooperation/ Vietnam/WBI-Vietnam-October-2011/Modelling/Monolix32-PKPD-library.pdf. [Accessed on 07 January 2013].
9. Cule E, Vineis P, De Iorio M. Significance testing in ridge regression for genetic data. BMC Bioinformatics 2011; 12:372.
10. Cule E, De Iorio M. A semi-automatic method to guide the choice of ridge parameter in ridge regression. ArXiv e-prints 2012; Available at: http://arxiv.org/pdf/1205.0686v1.pdf [Accessed on 07 January 2013].
11. Vignal C, Bansal A, Balding D. Using penalised logistic regression to fine map HLA variants for rheumatoid arthritis. Ann Hum Genet 2011; 75: 655-664.
12. Kappelhoff BS, Huitema ADR, Yalvaç Z, Prins JM, Mulder JW, Meenhorst PL, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44:849-861.
13. Bazzoli C, Retout S, Mentré F. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed 2010; 98:55-65.
14. Daly TM, Dumaual CM, Miao X, Farmen MW, Njau RK, Fu D-J, et al. Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. Clin Chem 2007; 53:1222-1230.
15. Su Z, Marchini J, Donnelly P. HAPGEN2: simulation of multiple disease SNPs. Bioinformatics 2011; 27:2304-2305.
16. Delyon B, Lavielle M, Moulines E. Convergence of a stochastic approximation version of the EM algorithm. Ann Statist 1999; 27:94-128.
17. Lavielle M. MONOLIX (MOdè les NOn LInéaires à effets miXtes). 2008. Available at: http://software.monolix.org/sdoms/software/. [Accessed on 07 January 2013].
18. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-569.
19. Senn S. Individual therapy: new dawn or false dawn. Drug Inf J 2001; 35:1479-1494.
20. Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8&z.ast;3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011; 11:113-120.
21. Bertrand J, Comets E, Laffont CM, Chenel M, Mentré F. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn 2009; 36:317-339.
22. Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, et al. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. J Pharmacokinet Pharmacodyn 2012; 39:393-414.
23. Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, et al. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenet Genomics 2011; 21:721-730.
24. Ribbiing J, Nyberg J, Caster O, Jonsson EN. The lasso-a novel method for predictive covariate model building in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn 2007; 34:485-517.